Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene expression subgroup rely upon chronic active B cell receptor signaling for viability, a dependency that is targetable by ibrutinib. A phase III trial (“Phoenix;” ClinicalTrials.gov: NCT01855750) showed a survival...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer cell 2021-12, Vol.39 (12), p.1643-1653.e3
Hauptverfasser:	Wilson, Wyndham H., Wright, George W., Huang, Da Wei, Hodkinson, Brendan, Balasubramanian, Sriram, Fan, Yue, Vermeulen, Jessica, Shreeve, Martin, Staudt, Louis M.
Format:	Artikel
Sprache:	eng
Schlagworte:	ABC DLBCL Adenine - analogs & derivatives Adenine - pharmacology Adenine - therapeutic use Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use BTK inhibitor cancer genomics CD79B Cyclophosphamide - pharmacology Cyclophosphamide - therapeutic use Doxorubicin - pharmacology Doxorubicin - therapeutic use Female Humans Lymphoma, Large B-Cell, Diffuse - drug therapy Male memory B cell Middle Aged MYD88 NOTCH1 Piperidines - pharmacology Piperidines - therapeutic use precision medicine Prednisone - pharmacology Prednisone - therapeutic use Rituximab - pharmacology Rituximab - therapeutic use Vincristine - pharmacology Vincristine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!